Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

被引：6

作者：

Aftimos, P. G. ^{[1
]}

Cortes, J. ^{[2
]}

Bidard, F. C. ^{[3
]}

Kaklamani, V. ^{[4
]}

Bardia, A. ^{[5
]}

Neven, P. ^{[6
]}

Streich, G. ^{[7
,8
]}

Montero, A.

Forget, F. ^{[9
]}

Reynier, M. A. Mouret ^{[10
]}

Sohn, J. ^{[11
]}

Taylor, D. ^{[12
]}

Harnden, K. ^{[13
]}

Khong, H. ^{[14
]}

Kocsis, J. ^{[15
]}

Dalenc, F. ^{[16
]}

Dillon, P. ^{[17
]}

Tonini, G. ^{[18
]}

Grzegorzewski, K. J. ^{[19
]}

Lu, J. ^{[20
]}

机构：

[1] Inst Jules Bordet, Clin Trials Conduct Unit, Brussels, Belgium

[2] Int Breast Canc Ctr IBCC, Quiron Grp, Med Oncol, Barcelona, Spain

[3] Inst Curie, Med Oncol Dept, Paris, France

[4] UTHSCSA Univ Texas Hlth Sci Ctr San Antonio, 303 Regent Circle, San Antonio, TX USA

[5] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Haematol Oncol, Boston, MA USA

[6] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Dept Gynaecol Oncol, Campus Gasthuisberg, Leuven, Belgium

[7] Hosp Mil Cent Cirujano Mayor Dr Cosme Argerich, Buenos Aires, Argentina

[8] Case Western Reserve Univ, Med Oncol, Cleveland, OH USA

[9] Ctr Hosp Ardenne, Med Oncol, Libramont, Belgium

[10] Jean Perrin Ctr, Med Oncol, Clermont Ferrand, France

[11] Yonsei Univ, Med Oncol Dept, Seoul, South Korea

[12] CHU UCL Namur Site St Elisabeth, Dept Oncol, Namur, Belgium

[13] Inova Schar Canc Inst, Med Oncol, Fairfax, VA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Med Oncol, Magnolia Campus, Tampa, FL USA

[15] Bacs Kiskun Cty Teaching Hosp Kecskemet, Oncol Dept, Kecskemet, Hungary

[16] Ctr Claudius Regaud, Clin Res, Toulouse, France

[17] UVA Univ Virginia, Med Oncol, Sch Med, Div Hematol & Oncol, Charlottesville, VA USA

[18] Menarini Silicon Biosyst Inc, North Amer Operat, Med Oncol, Huntingdon Valley, PA USA

[19] Stemline Therapeut Inc, Clin Dev, New York, NY USA

[20] USC Univ Southern Calif, Med Dept, Norris Comprehens Canc Ctr, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.259

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

220P

引用

页码：S638 / S638

页数：1

共 50 条

[21] Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2-advanced breast cancer: Phase 1 results.
Maglakelidze, Marina
Bulat, Iurie
Ryspayeva, Dinara
Krastev, Boris Milev
Gogiladze, Maia
Crijanovschi, Adrian
Aftimos, Philippe Georges
Neven, Patrick
Pegram, Mark D.
Menke, Catharina Wilhelmina
Dees, Elizabeth Claire
Schroder, Carolien P.
Jager, A.
Chap, Linnea I.
Hamilton, Erika P.
Cristofanilli, Massimo
Ulahannan, Susanna Varkey
Boers, Jorianne
Iqbal, Ramsha
Jain, Sarika
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/HER2-locally advanced or metastatic breast cancer
Wu, Jiong
Zhang, Jian
Zhang, Qingyuan
Sun, Yuping
Li, Hongtao
Yin, Yongmei
Shi, Yehui
Li, Wenfeng
Liu, Yunjiang
Yan, Min
Yang, Chen
Zhu, Lili
Yang, Yang
Xue, Liting
CANCER RESEARCH, 2024, 84 (09)
[23] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara
Loibl, Sibylle
Tolaney, Sara
Kaklamani, Virginia
Tonini, Giulia
Matheny, Shannon
Theall, Kathy Puvana
O'Shaughnessy, Joyce
CANCER RESEARCH, 2024, 84 (09)
[24] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope S.
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara A.
Loibl, Sibylle
Kummel, Sherko
Scartoni, Simona
Matheny, Shannon
Theall, Kathy Puyana
O'shaughnessy, Joyce
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
[25] Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer
Aftimos, Philippe
Maglakelidze, Marina
Glaudemans, Andor W. J. M.
Hamilton, Erika
Chap, Linnea
de Vries, Elisabeth
van Oordt, Catharina Willemien Menke-van der Houven
Jager, Agnes
Dees, E. Claire
Cristofanilli, Massimo
Pegram, Mark
Ulahannan, Susanna
Neven, Patrick
Bulat, Iurie
Rai, Ruhi
Tao, Wenli
Jain, Sarika
Beelen, Andrew P.
Sorrentino, Jessica A.
CANCER RESEARCH, 2021, 81 (04)
[26] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
Rugo, H. S.
O'Shaughnessy, J.
Cortes, J.
Bardia, A.
Hamilton, E. P.
Hurvitz, S. A.
Kaklamani, V.
Mchayleh, W.
Romero, P. Munoz
Vallespir, B. Piza
Wasserman, T.
Theall, K. P.
Tolaney, S. M.
ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
[27] Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2-locally advanced or metastatic breast cancer (ABC)
Dees, E. C.
Aftimos, P. G.
van Oordt, C. W. Menke-van der Houven
De Vries, E. G. E.
Neven, P.
Pegram, M. D.
Iqbal, R.
Boers, J.
Xiao, J.
Sipes, C.
Li, C.
Sorrentino, J. A.
Malik, R.
Beelen, A. P.
ANNALS OF ONCOLOGY, 2019, 30 : 121 - +
[28] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
Dickler, Maura N.
Villanueva, Rafael
Fidalgo, Jose Alejandro Perez
Mayer, Ingrid A.
Boni, Valentina
Winer, Eric P.
Hamilton, Erika P.
Bellet, Meritxell
Urruticoechea, Ander
Gonzalez-Martin, Antonio
Cortes, Javier
Martin, Miguel
Giltnane, Jennifer
Gates, Mary
Cheeti, Sravanthi
Fredrickson, Jill
Wang, Xiaojing
Friedman, Lori S.
Spoerke, Jill M.
Metcalfe, Ciara
Liu, Lichuan
Li, Robert
Morley, Roland
McCurry, Ursula
Chan, Iris T.
Mueller, Lars
Milan, Sandra
Lauchle, Jennifer
Humke, Eric W.
Bardia, Aditya
CANCER RESEARCH, 2018, 78 (04)
[29] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer
Jhaveri, Komal
Winer, Eric Paul
Lim, Elgene
Fidalgo, Jose AlejandroPerez
Bellet, Meritxell
Mayer, Ingrid Alina
Boni, Valentina
Patel, Jaymin M.
Bardia, Aditya
Garcia, Jose Manuel
Kabos, Peter
Gates, Mary
Chen, Ya-Chi
Fredrickson, Jill
Wang, Xiaojing
Friedman, Lori Sickels
Spoerke, Jill
Gendreau, Steven
Metcalfe, Ciara
Liu, Lichuan
Chang, Ching-Wei
Monemi, Sharareh
Gonzalez, Monica
McCurry, Ursula
Milan, Sandra
Humke, Eric William
Loi, Sherene
CANCER RESEARCH, 2020, 80 (04)
[30] Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
Campone, Mario
Bardia, Aditya
Ulaner, Gary A.
Chandarlapaty, Sarat
Gosselin, Alice
Doroumian, Severine
Pelekanou, Vasiliki
Celanovic, Marina
Linden, Hannah M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →